18FDG PET in oncology: The best and the worst (Review)
2006; Spandidos Publishing; Linguagem: Inglês
10.3892/ijo.28.5.1249
ISSN1019-6439
AutoresTarik Belhocine, Karoline Spaepen, Michelle Dusart, Cathérine Castaigne, Kristof Muylle, Pierre Bourgeois, Daniel J. Bourgeois, Lawrence Dierickx, Patrick Flamen,
Tópico(s)Radiomics and Machine Learning in Medical Imaging
ResumoThe clinical added-value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG PET) in the management of oncology patients is increasingly documented. In the present review, we discuss both the benefits and the limitations of 18FDG PET in different cancers. Considering the literature data and our own experience, we also indicate the best clinical approach to optimize the use of metabolic imaging in oncology.
Referência(s)